Form 8-K - Current report:
SEC Accession No. 0001628280-23-018467
Filing Date
2023-05-16
Accepted
2023-05-16 17:08:46
Documents
14
Period of Report
2023-05-16
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20230516.htm   iXBRL 8-K 37088
2 EX-99.1 caldolorfdaapprovallabelex.htm EX-99.1 8232
6 GRAPHIC image_0.jpg GRAPHIC 18457
  Complete submission text file 0001628280-23-018467.txt   211014

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20230516.xsd EX-101.SCH 2011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20230516_lab.xml EX-101.LAB 24152
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20230516_pre.xml EX-101.PRE 12609
8 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20230516_htm.xml XML 11014
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 23928582
SIC: 2834 Pharmaceutical Preparations